Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
cephalosporin |
| gptkbp:activeIn |
gptkb:Streptococcus_pneumoniae
gptkb:Pseudomonas_aeruginosa gptkb:methicillin-resistant_Staphylococcus_aureus |
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
J01DI03
|
| gptkbp:brand |
Mabelio
Zevtera |
| gptkbp:CASNumber |
627816-23-9
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developer |
gptkb:Basilea_Pharmaceutica
|
| gptkbp:eliminationHalfLife |
3 hours
|
| gptkbp:generation |
fifth-generation
|
| gptkbp:hasMolecularFormula |
C20H22N8O6S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
ceftobiprole
|
| gptkbp:indication |
community-acquired pneumonia
hospital-acquired pneumonia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:spectrumOfActivity |
broad-spectrum
|
| gptkbp:bfsParent |
gptkb:J01DH56
|
| gptkbp:bfsLayer |
6
|